Virtual Library
Start Your Search
B. Moore
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-079 - Targeting Antigen Presentation by Tumor Infiltrating B Cells to CD4 T Cells in Non-Small Cell Lung Cancer Patient Tumors (ID 3241)
09:30 - 09:30 | Author(s): B. Moore
- Abstract
Background:
B cells in tumors (TIL-Bs) are detected in non-small cell lung cancer (NSCLC) and their frequency correlates with improved survival, however, the functional mechanism of TIL-Bs in solid tumors is not well understood. We hypothesize that TIL-Bs help generate potent, long-term immune responses against cancer by presenting tumor antigens to CD4 tumor infiltrating lymphocytes (TILs) in primary human lung tumors.
Methods:
not applicable
Results:
Using un-manipulated, primary human B cells from fresh tumor, tumor-adjacent, and normal (cancer-free) lung tissue we observed that the total number of B cells at the site of the tumor versus the tumor-adjacent tissue was increased compared to other immune subsets. Further, in analyzing B cell markers of activation and exhaustion, we observed a spectrum of activation of TIL-Bs. Finally, we showed that TIL-Bs present autologous tumor antigens to CD4 TILs in a subset of NSCLC patients, and that depending on the activation or exhaustion profile of the TIL-Bs, differentiate CD4 TILs to T regulatory cells (Treg). These data suggest that some patients with TIL-Bs have differential function that is influenced by their activation or exhaustion phenotype.
Conclusion:
In conclusion, the anti-tumor functon of TIL-Bs can be stimulated in some NSCLC patients, and TIL-Bs that cannot be stimulated have increased immune exhaustion and promote Treg differentiation. Ultimately, results from this study will help predict which TIL-B functions to target in future TIL-B-specific immunotherapies or in combination with current immunotherapies for NSCLC patients like blockade of the inhibitory receptor, PD-1.
